These results suggest that nonabsorbable, intestine-targeting NHE3 inhibitors may be promising for the treatment of resistant hypertension in elder patients with constipation when combined with other already existing antihypertensive drugs by selectively inhibiting NHE3 and Na+ absorption from the gastrointestinal tract. This evidence concerns the gene SLC9A3 and Hypertension.